KURA ONCOLOGY

Kura Oncology is a clinical-stage biopharmaceutical company engaged in developing medicines for the treatment of cancer. The company's key product candidate, tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase. The company's second product candidate is KO-947, a potent and selective small molecule inhibitor of extracellular signal related kinase, which the company is advancing as a potential treatment for patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase signaling pathway. The company's third program is focused on KO-539, a selective small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction.
  • TickerKURA
  • ISINUS50127T1097
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for KURA

ValuEngine Rating and Forecast Report for KURA

ValuEngine Rating and Forecast Report for KURA

ValuEngine Rating and Forecast Report for KURA

Ashiq Mubarack ...
  • David Nierengarten
  • Robert Driscoll

Q1 Financials, PTCL Oral Presentations at EHA and ICML in June

Ashiq Mubarack ...
  • David Nierengarten
  • Robert Driscoll

Q1 Financials, PTCL Oral Presentations at EHA and ICML in June

ValuEngine Rating and Forecast Report for KURA

ValuEngine Rating and Forecast Report for KURA

ValuEngine Rating and Forecast Report for KURA

ValuEngine Rating and Forecast Report for KURA

ValuEngine Rating and Forecast Report for KURA

ValuEngine Rating and Forecast Report for KURA

ValuEngine Rating and Forecast Report for KURA

ValuEngine Rating and Forecast Report for KURA

ValuEngine Rating and Forecast Report for KURA

ValuEngine Rating and Forecast Report for KURA

ResearchPool Subscriptions

Get the most out of your insights

Get in touch